EP1339429A4 - Zusammensetzung enthaltend statine und calcium für verbesserte kardiovaskuläre gesundheit - Google Patents

Zusammensetzung enthaltend statine und calcium für verbesserte kardiovaskuläre gesundheit

Info

Publication number
EP1339429A4
EP1339429A4 EP01986043A EP01986043A EP1339429A4 EP 1339429 A4 EP1339429 A4 EP 1339429A4 EP 01986043 A EP01986043 A EP 01986043A EP 01986043 A EP01986043 A EP 01986043A EP 1339429 A4 EP1339429 A4 EP 1339429A4
Authority
EP
European Patent Office
Prior art keywords
vitamin
calcium
composition containing
cardiovascular health
improved cardiovascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01986043A
Other languages
English (en)
French (fr)
Other versions
EP1339429A2 (de
Inventor
Adrianne Bendich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1339429A2 publication Critical patent/EP1339429A2/de
Publication of EP1339429A4 publication Critical patent/EP1339429A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
EP01986043A 2000-11-29 2001-11-29 Zusammensetzung enthaltend statine und calcium für verbesserte kardiovaskuläre gesundheit Withdrawn EP1339429A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25389900P 2000-11-29 2000-11-29
US253899P 2000-11-29
PCT/US2001/044734 WO2002043659A2 (en) 2000-11-29 2001-11-29 Composition containing statins and calcium for improved cardiovascular health

Publications (2)

Publication Number Publication Date
EP1339429A2 EP1339429A2 (de) 2003-09-03
EP1339429A4 true EP1339429A4 (de) 2007-03-14

Family

ID=22962156

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01986043A Withdrawn EP1339429A4 (de) 2000-11-29 2001-11-29 Zusammensetzung enthaltend statine und calcium für verbesserte kardiovaskuläre gesundheit

Country Status (6)

Country Link
EP (1) EP1339429A4 (de)
JP (1) JP2004514684A (de)
AU (1) AU3651102A (de)
CA (1) CA2427618A1 (de)
MX (1) MXPA03004818A (de)
WO (1) WO2002043659A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4611622B2 (ja) * 2002-07-11 2011-01-12 第一三共株式会社 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
CN100341509C (zh) * 2002-07-11 2007-10-10 三共株式会社 用于改善血液中脂质或降低血液中高半胱氨酸的药物组合物
NZ569868A (en) * 2002-09-27 2010-01-29 Martek Biosciences Corp Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
NZ539625A (en) * 2002-09-27 2007-11-30 Martek Biosciences Corp Improved glycemic control for Prediabetes and/or Diabetes Type II Using Docosahexaenoic Acid
FR2847472B1 (fr) * 2002-11-22 2006-08-11 Synergia Nouvelles compositions pharmaceutiques notamment pour la prevention des pathologies cardio-vasculaires
DE10261067A1 (de) * 2002-12-24 2004-08-05 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
CA2549116A1 (en) * 2003-12-23 2005-07-07 Medicure International Inc. Combination therapies employing a composition comprising a hmg coa reductase inhibitor and a vitamin b6 related compound
ITRM20040395A1 (it) * 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
BRPI0514189A (pt) * 2004-08-06 2008-06-03 Transform Pharmaceuticals Inc composições farmacêuticas de estatina e métodos de tratamento relacionados
BRPI0513939A (pt) * 2004-08-23 2008-05-20 Unilever Nv composição, formador de creme e/ou clareador, composição de alimento, processo para a manufatura de uma composição e uso de uma composição
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
US20060211762A1 (en) * 2004-12-06 2006-09-21 Rongen Roelof M Omega-3 fatty acids and dyslipidemic agent for lipid therapy
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
RU2008108078A (ru) * 2005-08-04 2009-09-10 Трансформ Фармасьютикалз, Инк. (Us) Новые препаративные формы, включающие фенофибрат и статин, и соответствующие способы лечения
CA2628305C (en) * 2005-11-11 2014-05-06 Mochida Pharmaceutical Co., Ltd. Jelly composition
WO2007103557A2 (en) * 2006-03-09 2007-09-13 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
ITMI20072142A1 (it) * 2007-11-08 2009-05-09 Yervant Zarmanian Composizioni farmaceutiche contenenti statine e derivati di acidi grassi omega-3
KR20110039249A (ko) * 2008-07-07 2011-04-15 모치다 세이야쿠 가부시키가이샤 지질 이상증의 개선 또는 치료약
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
GB0818472D0 (en) * 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.
WO2011047259A1 (en) * 2009-10-16 2011-04-21 Glaxosmithkline Llc Compositions
KR20120104270A (ko) 2009-12-23 2012-09-20 데피안떼 파마슈띠까 에스.에이. 심혈관계 질환 치료에 유용한 복합 조성물
EP2654463B1 (de) * 2010-12-21 2018-05-30 Omegatri AS Antioxidantien in fischölpulver und tabletten
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
FR3007985A1 (fr) * 2013-07-02 2015-01-09 Internat Nutrition Res Company Medicament pour la prevention et le traitement des facteurs de risques cardiometaboliques, en particulier maladies cardiovasculaires, pre-diabete, diabete de type ii et steatose hepatique
FR3007986A1 (fr) * 2013-07-02 2015-01-09 Internat Nutrition Res Company Medicament destine a lutter contre l'infertilite et la sous-fertilite en particulier dans le cadre d'une sous fertilite ou infertilite metabolique
FR3007987A1 (fr) * 2013-07-02 2015-01-09 Internat Nutrition Res Company Medicament pour la prevention et le traitement de l'atherosclerose et du survieillissement metabolique
WO2015000986A1 (fr) * 2013-07-02 2015-01-08 International Nutrition Research Company Composition intervenant dans la regulation du dysfonctionnement des cycles de l'energie, de l'inflammation et de l'insulinoresistance et son utilisation notamment dans les maladies cardiometaboliques
EP3442517A1 (de) * 2016-04-14 2019-02-20 Lucey, Michael Kombinationszusammensetzungen und verfahren zur verwendung davon

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039053A2 (en) * 1995-06-06 1996-12-12 Campbell Soup Company Mineral supplements for dietetic food
WO1997038694A1 (en) * 1996-04-17 1997-10-23 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940727A (en) * 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
PT843972E (pt) * 1996-11-20 2002-12-31 Nutricia Nv Composicao nutritiva que inclui gorduras para o tratamento do sindrome metabolico

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039053A2 (en) * 1995-06-06 1996-12-12 Campbell Soup Company Mineral supplements for dietetic food
WO1997038694A1 (en) * 1996-04-17 1997-10-23 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease

Also Published As

Publication number Publication date
WO2002043659A2 (en) 2002-06-06
AU3651102A (en) 2002-06-11
EP1339429A2 (de) 2003-09-03
MXPA03004818A (es) 2003-09-10
CA2427618A1 (en) 2002-06-06
JP2004514684A (ja) 2004-05-20
WO2002043659A3 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
WO2002043659A3 (en) Composition containing statins and calcium for improved cardiovascular health
US7786175B2 (en) Anti-atherosclerosis composition containing carotenoids and method for inhibiting LDL oxidation
MY162133A (en) Nutritional supplement containing long-chain polyunsaturated fatty acids
RU2008116611A (ru) Способ снижения артериального давления у индивидов с состоянием, предшествующим гипертензии, и/или у индивидов с метаболическим синдромом
AU2001255114A1 (en) Preparation for the prevention and/or treatment of vascular disorders
US20050233944A1 (en) Arginine compositions for coordinate modification of multiple cardiovascular risk factors
NZ516101A (en) Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents
DE60005152D1 (de) Arzneimittel, nahrungszusätze und kosmetische zubereitung enthaltend eine fettsäure und ingwer
JP2002514574A (ja) 圧迫性潰瘍の治療のための栄養組成物
WO2005110375A8 (en) Nutritional supplement for treatment of ocular diseases
DE60330542D1 (de) Pharmazeutische Zubereitung enthaltend einen NMDA Rezeptor Agonisten für die Behandlung von Bewegungsstörungen
MXPA04000834A (es) Suplementos dieteticos de vinasa de vino y un proceso importante de produccion.
WO2006108692A3 (en) Dosage form for oral administration of a vitamin
WO2002056708A3 (de) Zubereitung zur verbesserung der nahrungsverwertung
CY1105732T1 (el) Μυρμηκικο ασβεστιο ως διαιτητικο συμπληρωμα
CA2556520A1 (en) Chromium-fatty acid compounds and methods of making and using thereof
AU2002226652A1 (en) An anti-atherosclerosis composition containing carotenoids and method for inhibiting LDL oxidation
WO2002043662A3 (en) Dietary composition containing conjugated linoleic acid and calcium for improved health
WO2003049687A3 (en) Medicinal compositions & therapeutic methods
CA2408528A1 (en) Creatine salt having enhanced nutritional and therapeutic efficacy and compositions containing same
WO2003002125A3 (en) Combination of aminosugars and cysteine or cysteine derivatives
PL367812A1 (en) Alpha-ketoglutarates of active ingredients and compositions containing same
WO2001024803A3 (en) Pharmaceutical compositions containing copper, salicylic acid and vitamines c
WO2003097033A3 (fr) Nouvelle compositions neutraceutiques et pharmaceutiques et leurs utilisations
WO2003049668A3 (en) Method of administering calcium citrate

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030624

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

R17D Deferred search report published (corrected)

Effective date: 20020906

A4 Supplementary search report drawn up and despatched

Effective date: 20070208

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/20 20060101ALI20070202BHEP

Ipc: A61K 31/525 20060101ALI20070202BHEP

Ipc: A61K 31/366 20060101ALI20070202BHEP

Ipc: A61K 31/714 20060101ALI20070202BHEP

Ipc: A61K 31/4415 20060101ALI20070202BHEP

Ipc: A61K 31/375 20060101ALI20070202BHEP

Ipc: A61K 31/355 20060101ALI20070202BHEP

Ipc: A61K 47/00 20060101AFI20020919BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070510